189 search results for: Clinical Management
Emerging Therapeutics: Addressing the Gaps in CSU Patient Care
In this video from EADV 2025, Professor Metz shares exciting data from therapies recently approved or in late-stage development for CSU.
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
Impact of Advanced Systemic Therapies on Disease Control in AD
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
Current systemic therapies have been shown to induce remission in a subset of AD patients
Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.
Can early intervention modify the course of AD?
Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.
Early Intervention and the Potential for Disease Modification in Children With AD
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Amy Paller discussing the benefits of early intervention for children with AD and the potential for disease modification. Dr. Paller also reviews available data investigating the impacts of therapies for AD on the disease itself and on associated comorbidities.
What is Early Intervention in AD?
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Eulàlia Baselga, Dr. Amy Paller, and Dr. Lisa Weibel share their views on what “early” means when discussing early intervention in AD.
Disease Modification in AD
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Amy Paller discusses the benefits of early intervention for children with AD and the potential for disease modification.
When is the right time to consider a biologic in patients with CRSwNP?
Prof. Hellings and Prof. Corso explain that the right time to implement a biologic depends on academic and reimbursement criteria, which vary by country.
Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission
It Takes a Village: Patient-Centered Care in Pediatric EoE
Learn from Prof. Papadopoulou as she highlights the importance of collaboration of multiple specialties in the care of pediatric EoE.
Dr. Giorgio Canonica Regarding Multidisciplinary Approach
This video clip from the EAACI 2024 symposium highlights that a multidisciplinary approach is essential for the treatment of asthma.
